Cytokine induced killer (CIK) cells has been increasingly used in adoptive immunotherapy against various cancers and viral infections. This review summarizes the basic overview of CIK cells as a therapeutic immunocyte. Herein, the basic concepts on CIK cells, their general characteristics, approaches in enhancing their functions, cytotoxic mechanism of CIK cells and their therapeutic benefits in tumors and viral infections are explored.
INTRODUCTION
Immunotherapy has emerged as a promising treatment option to boost immune response to defense against diseases and infections. The two immunotherapeutic options include active and passive immunotherapy. Active immunotherapy mainly refers to vaccines, immune adjuvants and cytokines which can activate endogenous immune system. On the other hand, the latter consists of immune modulating antibody-based therapy and adoptive immunotherapy which provides or strengthen immune reaction in patients by infusing antibodies or effector cells produced in vitro 1 .
ADOPTIVE IMMUNOTHERAPY
Over the past two decades, adoptive transfer of immunocytes has been increasingly used in treatment of cancers and viral infections Previously, TIL and LAK used to be the best candidate for adoptive immunotherapy. However, limitations to obtain sufficient number of immune effectors cells, higher alloreactivity and inability to show antitumor property effectively attracted the researchers to seek for additional and better-tolerated strategy 3 . With the initial report of Schmidt-Wolf et al 4 (1991) CIK cells has been identified as a promising candidate of adoptive immunotherapy that holds all the desired properties.
CYTOKINE INDUCED KILLER CELLS AND THEIR GENERAL CHARACTERISTICS
CIK cells are ex-vivo expanded T cells that display phenotypic and functional characteristics of both NK cells and cytotoxic T cells 5 . As these cells were generated under the influence of cytokines and mediate the potent MHCunrestricted cytotoxicity against various types of cancer, | Review Education they were named as "cytokine induced killer" cells. Briefly, CIK cells were generated by culturing interferon gamma (IFN-γ) activated human peripheral blood mononuclear cells (PBMC) in presence of cluster of differentiation 3 (CD3) antibody, interleukin 1 (IL-1) and IL-2 for 21 days 4, 6, 7 . These ex-vivo expanded cells were used for targeted treatment of human disease 1, 8 . 
SOURCE FOR CIK CELLS
PBMC is given the first priority to generate these cells in humans 4, 15 . However, expansion of human CIK cells from cord blood had been achieved 16, 17 . Moreover, CIK cells were generated from splenocytes 18 thymus 13,19 lymph nodes 20 and bone marrow 19 of murine models.
IMPROVING CIK CELL PROLIFERATION AND FUNCTION
Since the first report of CIK cells by Schmidt-Wolf et al 4 in 1991, various groups of researchers focused on improving both the expansion and anti-tumor cytotoxicity of CIK cells. The use of cytokines other than IL-2 or the co-culture of CIK cells with dendritic cells (DCs) and even the suppression of regulatory T cells (Tregs) within the CIK cell culture are the major modification being performed [21] [22] [23] [24] . ; however the detailed underlying mechanism is still unknown.
CYTOTOXIC MECHANISM OF CIK CELLS
CIK cells are endowed with potent MHC-unrestricted cytotoxicity against both syngeneic and allogenic hematological and solid malignancies. The antitumor activity is mainly associated with CD3 + CD56
+ fraction as this fraction of cells has higher proportion of CD8 + cells. The exact mechanism involved in tumor recognition and killing by CIK cells is not completely known. However, cytotoxic granules like perforin and granzymes were proposed to be a mediator of cytolysis 35 Table 1 . . Epstein-Barr virus 49 or cytomegalovirus 50 . This antiviral activity could be due to the production of IFN-γ, TNF-α, perforin and granzyme B by CIK cells.
CONTRAINDICATIONS OF CIK CELL IMMUNOTHERAPY
There are many clinical studies using the CIK cells as immunotherapy. Till date, no severe side effects have been reported after CIK treatment. The most common side-effects were fever, chills, headache, rash, nausea, and vomiting occurring during or after transfusion. These could easily be treated with symptomatic therapy in case they did not resolve on their own within 24 hours 51, 52 . This indicates that CIK therapy is safe for clinical application although larger population cohorts should be investigated.
CONCLUSIONS
CIK cells were used as an adoptive immunotherapy against various cancers and some viral infections. However, the effectiveness varies with different clinical settings, mainly due to different approaches followed in their generation. Hence, further studies are warranted to enhance the expansion and cytolytic function of the CIK cells. Moreover, the beneficial use of CIK cell in various viral infections needs to be investigated.
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